May 8th 2024
For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
The PARP inhibitor olaparib (Lynparza) provides clinically significant, long-term treatment benefits in patients with platinum-sensitive relapsed serous ovarian cancer, according to the protocol-specified final overall survival (OS) analysis of the phase II Study 19 trial presented during the 2017 ASCO Annual Meeting.
Read More
Results for Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer
June 4th 2017Michael Birrer, MD, PhD, Director, University of Alabama Comprehensive Cancer Center, discusses adverse event results of the phase III SOLO2 trial, which explored maintenance olaparib (Lynparza) tablets in patients with <em>BRCA</em>-mutated platinum-sensitive relapsed serous ovarian cancer.
Watch
Second Surgery Extends Progression-Free Survival in Recurrent Ovarian Cancer With Positive AGO Score
June 4th 2017A second cytoreductive surgery followed by platinum-based chemotherapy extended progression-free survival (PFS) compared with platinum-based chemotherapy alone in patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score.
Read More
Comparing Neoadjuvant Chemotherapy Versus Surgery in Ovarian Cancer Care
June 1st 2017Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses which patients with ovarian cancer are better candidates for neoadjuvant chemotherapy versus surgery.
Watch
Benefit of Bevacizumab Varies Among Ovarian Cancer Subtypes
May 24th 2017Bevacizumab demonstrated superior progression-free survival and a trend toward improved overall survival (OS) in patients with proliferative or mesenchymal ovarian tumors compared with patients with immunoreactive or differentiated tumors.
Read More
Using Methylation as a Predictor for Response in Ovarian Cancer
May 10th 2017Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, discusses a study that explored methylation as a predictor for response in ovarian cancer.
Watch
Early Data Shows Promise for Novel Combo in Ovarian Cancer
May 5th 2017The combination of the investigational agent birinapant and carboplatin could eliminate platinum-resistant, high-grade serous carcinoma (HGSC) ovarian tumor cells, according to preclinical findings published in <em>Precision Oncology.</em>
Read More
Expert Stresses Importance of Genetic Testing in Ovarian Cancer
April 18th 2017Mike Janicek, MD, sheds light on why physicians are slow to educate patients on genetic testing, the detection of genes aside from <em>BRCA1/2</em>, and the lesser-known benefits of getting genetic testing early on in a diagnosis.
Read More
Expert Discusses Why Chemotherapy Remains a Mainstay in Frontline Ovarian Cancer Management
April 12th 2017Heather Dalton, MD, discusses first-line treatment options currently available for patients, pivotal data that have solidified standard approaches, and why chemotherapy will likely always remain critical in the ovarian cancer sphere.
Read More
Novel RAF Inhibitor BGB-283 Active in Multiple Tumor Types
April 6th 2017BGB-283, a novel agent that targets <em>RAS/RAF</em>-mutated tumors, demonstrated activity across a variety of tumor types, according to the results of a preliminary clinical evaluation presented at the 2017 AACR Annual Meeting.
Read More
Niraparib Approved by FDA for Ovarian Cancer
March 27th 2017The PARP inhibitor niraparib (Zejula) has been approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
Read More
New Screening Approach Is a Step Toward an Effective Way to Delay Oophorectomy, Expert Says
March 27th 2017Steven J. Skates, PhD, discusses a study on early detection of ovarian cancer using the Risk of Ovarian Cancer Algorithm (ROCA), in which CA125 was tested in women with high risk who chose to postpone surgery.
Read More
Immune Stimulant No Help When Added to Chemotherapy for Recurrent Ovarian Cancer
March 16th 2017Adding an immunotherapeutic agent to chemotherapy had no impact on survival in patients with recurrent, platinum-resistant ovarian cancer, according to a late-breaking trial reported at the 2017 Society of Gynecologic Oncology Annual Meeting.
Read More
Big Increase in PFS With Maintenance Olaparib for BRCA+ Ovarian Cancer
March 15th 2017Patients with relapsed, platinum-sensitive <em>BRCA</em>-mutant ovarian cancer experienced a 13.6-month improvement in progression-free survival (PFS) with the PARP inhibitor olaparib versus placebo, according to data reported at the Society of Gynecologic Oncology meeting.
Read More
Carboplatin Desensitization Leads to Improved OS in Ovarian Cancer
March 15th 2017Patients with <em>BRCA</em>-proficient ovarian cancer who were treated with a carboplatin desensitization regimen had an improved overall survival (OS), according to a retrospective analysis reported at the 2017 Society of Gynecologic Oncology Annual Meeting.
Read More
Expert Discusses Success Seen With Niraparib Maintenance Therapy for Ovarian Cancer
March 15th 2017Ursula A. Matulonis, MD, discusses results of the phase III NOVA trial showed the PARP inhibitor niraparib demonstrated an improvement in PFS versus placebo as a maintenance therapy for patients with high-grade serous ovarian cancer.
Read More
Neoadjuvant Chemotherapy for Patients With High-Grade Endometrial Cancer
March 14th 2017Alon Altman, MD, associate professor, Department of Obstertrics, Gynecology and Reproductive Sciences, University of Manitoba, discusses neoadjuvant chemotherapy for patients with high-grade serous carcinoma. Across the world, many centers have shifted to more patients receiving neoadjuvant chemotherapy followed by surgery and further chemotherapy.
Watch